
Opinion|Videos|December 22, 2023
Monitoring Patients on Treatment for MF
Author(s)Aaron T. Gerds, MD, MS
Aaron Gerds, MD, MS, explains that myelofibrosis patients on JAK inhibitors need regular monitoring of blood counts, liver enzymes, and cardiac events to check for reactivation.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5








































